Inclusion Criteria

Inclusion Criteria

Patients must meet the following criteria to be eligible for the study:

- Histologically or cytologically documented evidence of colorectal cancer with at
least one measurable lesion (if previous radiation treatment, the target lesion must
have demonstrated progression since the radiation)

- The patient should have failed or progressed on no more than two prior chemotherapies
for metastatic disease (the prior chemotherapy must have included a fluoropyrimidine
and either Irinotecan or oxaliplatin, or any combination of these agents, with the
last chemotherapy having contained Irinotecan or oxaliplatin)

- Patients who have received only adjuvant therapy for their disease are eligible, as
long as they have relapsed within six months of completing such therapy and that
therapy contained 5-FU and Irinotecan or oxaliplatin administered in combination as
part of an investigational protocol

- Must have a life expectancy of greater than three (3) months.

Exclusion Criteria

The following patients are not eligible for the study:

- Patients with symptomatic CNS metastases or leptomeningeal involvement

- Patients with unresolved bowel obstruction

- Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1

- Patients with severe cardiac insufficiency

- Patients who have undergone major surgery for any cause less than 4 weeks prior to
study entry

- Patients with radiation therapy or chemotherapy within the last four weeks

- Patients taking Coumadin or other warfarin-containing agents with the exception of
low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports

- History of another malignancy within 5 years prior to study entry except curatively
treated non-melanoma skin cancer or cervical cancer in situ

- Patients with active or suspected acute or chronic uncontrolled infection including
abcesses or fistulae

- HIV+ patients

- Pregnant or lactating females